Swiss recommendations for the management of varicella zoster virus infections

Swiss Medical Weekly

Volumn 137, Issue 17-18, 2007, Pages 239-251

  Kempf, Werner ^a   Meylan, P ^b   Gerber, S ^b   Aebi, C ^c   Agosti, R ^d   Buchner S ^e   Coradi, B ^f   Garweg, J ^g   Hirsch, H H ^h,i   Kind, C ^j   Lauper, U ^k   Lautenschlager, S ^l   Reusser, P ^m   Ruef, C ^k   Wunderli, W ⁿ   Nadal, D ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Universitats Kinderklinik   (Switzerland)

^d Kopfwehzentrum Hirslanden   (Switzerland)

^e Universitatsspital Basel Dermatologie   (Switzerland)

^f Praxisgemeinschaft Affoltern   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY OF BASEL   (Switzerland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

^j Ostschweizer Kinderspital   (Switzerland)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l Dermatologisches Ambulatorium Triemli   (Switzerland)

^m Hôpital du Jura   (Switzerland)

ⁿ CHUG Genf   (Switzerland)

more..

Author keywords

Acyclovir; Brivudine; Chickenpox; Famiciclovir; Herpes zoster; Shingles; Valaciclovir; Varicella zoster virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMITRIPTYLINE; CAPSAICIN; CARBAMAZEPINE; FAMCICLOVIR; FOSCARNET; GABAPENTIN; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PREGABALIN; STEROID; TRAMADOL; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ACUPUNCTURE; ALTERNATIVE MEDICINE; BACTERIAL INFECTION; CHICKENPOX; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENCEPHALITIS; EVIDENCE BASED MEDICINE; EYE DISCOMFORT; HEALTH CARE COST; HEALTH PROGRAM; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; INCIDENCE; INFECTION CONTROL; LOADING DRUG DOSE; MEDICAL RESEARCH; MORBIDITY; MYELITIS; NEUROLOGIC DISEASE; PATIENT CARE; PNEUMONIA; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PREGNANCY; PROPHYLAXIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCAR FORMATION; SINGLE DRUG DOSE; SKIN DISEASE; SWITZERLAND; TREATMENT PLANNING; VACCINATION; VARICELLA ZOSTER VIRUS; VERTICAL TRANSMISSION; VIRUS INFECTION;

EID: 34250354798     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544): 1365-76.
2. Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-zoster virus infection. Ann Intern Med. 1999;130 (11):922-32.
3. Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol. 2003;70(Suppl 1): S9-14.
4. Weller TH. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983;309(22):1362-8.
5. Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. Scand J Soc Med. 1990;18(3):171-4.
6. Dunkle LM, Arvin AM, Whitley RJ, Rotbart HA, Feder HM Jr, Feldman S, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991;325(22):1539-44.
7. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis. 2002;13(1):12-21.
8. Kempf W, Lautenschlager S. Infections with varicella zoster virus. Hautarzt. 2001;52(4):359-76.
9. Jaeggi A, Zurbruegg RP, Aebi C. Complications of varicella in a defined central European population. Arch Dis Child. 1998; 79(6):472-7.
10. Abzug MJ, Cotton MF. Severe chickenpox after intranasal use of corticosteroids. J Pediatr. 1993;123(4):577-9.
11. Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92(2):223-8.
12. Junker AK, Angus E, Thomas EE. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Pediatr Infect Dis J. 1991;10(8):569-75.
13. Hurwitz ES, Goodman RA. A cluster of cases of Reye syndrome associated with chickenpox. Pediatrics. 1982;70(6):901-6.
14. Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield EC, III. Treatment of adult varicella with oral acyclovir. A randomized, placebo-controlled trial. Ann Intern Med. 1992;117 (5):358-63.
15. Hoglund M, Ljungman P, Weller S. Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother. 2001;47(6):855-61.
16. Seward J, Galil K, Wharton M. Epidemiology of varicella. In: Arvin AM, Gershon AA, editors. Varicella-zoster virus. Virology and clinical management. Cambridge: Cambridge University Press; 2000. p. 187-205.
17. Miller E, Marshall R, Vurden J. Epidemiology outcome and control of varicella zoster infection. Rev Med Microbiol. 1993: 222-30.
18. Mohsen AH, McKendrick M. Varicella pneumonia in adults. Eur Respir J. 2003;21(5):886-91.
19. Gnann JW, Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186(Suppl 1):S91-S98.
20. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis. 1995;172 (3):706-12.
21. Brown TJ, McCrary M, Tyring SK. Antiviral agents: Nonantiretroviral (correction of Nonantiviral) drugs. J Am Acad Dermatol. 2002;47(4):581-99.
22. Reusser P. Infections in the immunocompromised host: Opportunistic viral infections. In: Cohen J, Powderly WG, editors. Infectious diseases. London: Mosby; 2004. p. 1169-81.
23. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis. 1985;152(6):1172-81.
24. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant. 1994;13(3): 277-83.
25. Feldman S, Lott L. Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics. 1987;80(4):465-72.
26. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev. 1997;10(1):86-124.
27. Reusser P. Management of viral infections. In: Klastersky J, Schimpff SC, Senn H-J, editors. Supportive care in cancer: a handbook for oncologists. 2nd ed. New York: Marcel Dekker, Inc.; 1999. p. 87-112.
28. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001; 19(1):13-22.
29. Fox GN, Strangarity JW. Varicella-zoster virus infections in pregnancy. Am Fam Physician. 1989;39(2):89-98.
30. Chapman SJ. Varicella in pregnancy. Semin Perinatol. 1998;22 (4):339-46.
31. Maupin RT. Obstetric infectious disease emergencies. Clin Obstet Gynecol. 2002;45(2):393-404.
32. Smego RA, Jr., Asperilla MO. Use of acyclovir for varicella pneumonia during pregnancy. Obstet.Gynecol. 1991;78(6): 1112-6.
33. Pickard RE. Varicella pneumonia in pregnancy. Am J Obstet Gynecol. 1968;101(4):504-8.
34. Esmonde TF, Herdman G, Anderson G. Chickenpox pneumonia: an association with pregnancy. Thorax. 1989;44(10):812-5.
35. Potgieter PD, Hammond JM. Intensive care management of varicella pneumonia. Respir Med. 1997;91(4):207-12.
36. Broussard RC, Payne DK, George RB. Treatment with acyclovir of varicella pneumonia in pregnancy. Chest. 1991;99(4): 1045-7.
37. Siegel M, Fuerst HT, Peress NS. Comparative fetal mortality in maternal virus diseases. A prospective study on rubella, measles, mumps, chicken pox and hepatitis. N Engl J Med. 1966;274:768-71.
38. Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343(8912): 1548-51.
39. Jones KL, Johnson KA, Chambers CD. Offspring of women infected with varicella during pregnancy: a prospective study. Teratology. 1994;49(1):29-32.
40. Isada NB, Paar DP, Johnson MP, Evans MI, Holzgreve W, Qureshi F, et al. In utero diagnosis of congenital varicella zoster virus infection by chorionic villus sampling and polymerase chain reaction. Am J Obstet Gynecol. 1991;165(6 Pt 1):1727-30.
41. Cuthbertson G, Weiner CP, Giller RH, Grose C. Prenatal diagnosis of second-trimester congenital varicella syndrome by virus-specific immunoglobulin M. J Pediatr 1987;111(4):592-5.
42. Champion F, Rebaud A, Golfier F, Raudrant D. la ponction de sang foetal est-elle justifiée pour le diagnostic intra-uterin de la varicelle congénitale? Med Foetale Echo Gynecol. 1994:20-2.
43. Pretorius DH, Hayward I, Jones KL, Stamm E. Sonographic evaluation of pregnancies with maternal varicella infection. J Ultrasound Med. 1992;11(9):459-63.
44. Gershon AA. Chickenpox, Measles and Mumps. In: Remington J, Klein J, editors. Infectious Diseases of the Fetus and Newborn Infant. 5th ed. Philadelphia: WB Saunders; 2001. p. 683-732.
45. Enders G. Varicella-zoster virus infection in pregnancy. Prog Med Virol. 1984;29:166-96.
46. Kind C, Duc G. Prenatal and perinatal infections - problems for the practicing pediatrician: group B streptococci, varicella, toxoplasmosis. Schweiz Med Wochenschr. 1996;126(7):264-76.
47. Meyers JD. Congenital varicella in term infants: risk reconsidered. J Infect Dis. 1974;129(2):215-7.
48. Herrmann KL. Congenital and perinatal varicella. Clin Obstet Gynecol. 1982;25(3):605-9.
49. Miller E, Cradock-Watson JE, Ridehalgh MK. Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet. 1989;2(8659):371-3.
50. Preblud SR, Bregman DJ, Vernon LL. Deaths from varicella in infants. Pediatr Infect Dis. 1985;4(5):503-7.
51. Friedman CA, Temple DM, Robbins KK, Rawson JE, Wilson JP, Feldman S. Outbreak and control of varicella in a neonatal intensive care unit. Pediatr Infect Dis J. 1994;13(2):152-4.
52. Stover BH, Cost KM, Hamm C, Adams G, Cook LN. Varicella exposure in a neonatal intensive care unit: case report and control measures. Am J Infect Control. 1988;16(4):167-72.
53. Hanngren K, Grandien M, Granstrom G. Effect of zoster immunoglobulin for varicella prophylaxis in the newborn. Scand J Infect Dis. 1985;17(4):343-7.
54. Bakshi SS, Miller TC, Kaplan M, Hammerschlag MR, Prince A, Gershon AA. Failure of varicella-zoster immunoglobulin in modification of severe congenital varicella. Pediatr Infect Dis. 1986;5(6):699-702.
55. Haddad J, Simeoni U, Messer J, Willard D. Perinatal varicella. Lancet. 1986;1(8496):1494-5.
56. Holland P, Isaacs D, Moxon ER. Fatal neonatal varicella infection. Lancet. 1986;2(8516):1156.
57. King SM, Gorensek M, Ford-Jones EL, Read SE. Fatal varicella-zoster infection in a newborn treated with varicella-zoster immunoglobulin. Pediatr Infect Dis. 1986;5(5):588-9.
58. Reynolds L, Struik S, Nadel S. Neonatal varicella: varicella zoster immunoglobulin (VZIG) does not prevent disease. Arch Dis Child Fetal Neonatal Ed. 1999;81(1):F69-F70.
59. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep. 1996; 45(RR-11):1-36.
60. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
61. Ragozzino MW, Melton LJ, III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982;61(5):310-6.
62. Gnann JW, Jr., Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347(5):340-6.
63. Burgoon CF Jr, Burgoon JS, Baldridge GD. The natural history of herpes zoster. J Am Med Assoc. 1957;164(3):265-9.
64. Vu AQ, Radonich MA, Heald PW. Herpes zoster in seven disparate dermatomes (zoster multiplex): report of a case and review of the literature. J Am Acad Dermatol. 1999;40(5 Pt 2):868-9.
65. Kleinschmidt-DeMasters BK, Gilden DH. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med. 2001;125(6):770-80.
66. Volpi A, Gross G, Hercogova J, Johnson RW. Current management of herpes zoster: the European view. Am J Clin Dermatol. 2005;6(5):317-25.
67. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44Suppl 1:S1-S26.
68. Christiansen NP, Haake RJ, Hurd DD. Early herpes zoster infection in adult patients with Hodgkin's disease undergoing autologous bone marrow transplant. Bone Marrow Transplant. 1991;7(6):435-7.
69. Whitley RJ, Gnann JW, Jr. Herpes zoster in patients with human immunodeficiency virus infection - an ever-expanding spectrum of disease. Clin Infect Dis. 1995;21(4):989-90.
70. McCrary ML, Severson J, Tyring SK. Varicella zoster virus. J Am Acad Dermatol. 1999;41(1):1-14.
71. Zaal MJ, Volker-Dieben HJ, D'Amaro J. Visual prognosis in immunocompetent patients with herpes zoster ophthalmicus. Acta Ophthalmol Scand. 2003;81(3):216-20.
72. Croen KD, Ostrove JM, Dragovic LJ, Straus SE. Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci. U.S.A 1988;85(24):9773-7.
73. Liesegang TJ. Varicella-zoster virus eye disease. Cornea. 1999; 18(5):511-31.
74. Tabery HM. Corneal epithelial keratitis in herpes zoster ophthalmicus: «delayed» and «sine herpete». A non-contact photomicrographic in vivo study in the human cornea. Eur J Ophthalmol. 2002:12(4):267-75.
75. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000;107(8):1507-11.
76. Hoang-Xuan T, Buchi ER, Herbort CP, Denis J, Frot P, Thenault S, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99(7):1062-70.
77. Tyring S, Engst R, Corriveau C, Robillard N, Trottier S, Van Slycken S, et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol. 2001; 85(5):576-81.
78. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39(7):1546-53.
79. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis. 1998;178(Suppl 1):S81-S84.
80. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330(13):896-900.
81. Petursson G, Helgason S, Gudmundsson S, Sigurdsson JA. Herpes zoster in children and adolescents. Pediatr Infect Dis J. 1998;17(10):905-8.
82. Feder HM Jr, Hoss DM. Herpes zoster in otherwise healthy children. Pediatr Infect Dis J. 2004;23(5):451-7.
83. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ. 2000;321(7264):794-6.
84. Arvin A. Varicella-zoster virus. In: Long S, Pickering L, Prober CG, editors. Principles and Practice of Pediatric Infectious Diseases. 2nd ed. New York: Churchill Livingstone; 2003. p. 1041-50.
85. Jaamaa S, Salonen M, Seppala I, Piiparinen H, Sarna S, Koskiniemi M. Varicella zoster and Borrelia burgdorferi are the main agents associated with facial paresis, especially in children. J Clin Virol. 2003;27(2):146-51.
86. Tarlow MJ, Walters S. Chickenpox in childhood. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect. 1998;36(Suppl 1):39-47.
87. Brazin SA, Simkovich JW, Johnson WT. Herpes zoster during pregnancy. Obstet Gynecol. 1979;53(2):175-81.
88. Nathwani D, Maclean A, Conway S, Carrington D. Varicella infections in pregnancy and the newborn. A review prepared for the UK Advisory Group on Chickenpox on behalf of the British Society for the Study of Infection. J Infect. 1998;36(Suppl 1):59-71.
89. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.
90. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36(7):877-82.
91. Dworkin RH, Perkins FM, Nagasako EM. Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin J Pain 2000;16(2 Suppl):S90-100.
92. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2(7):e164.
93. Wassilew SW. Zoster-associated neuralgias. J Dtsch Dermatol Ges. 2006;4(10):871-9.
94. Ragozzino MW, Melton LJ, III, Kurland LT, Chu CP, Perry HO. Risk of cancer after herpes zoster: a population-based study. N Engl J Med. 1982;307(7):393-7.
95. Fueyo MA, Lookingbill DP. Herpes zoster and occult malignancy. J Am Acad Dermatol. 1984;11(3):480-2.
96. Wurzel CL, Kahan J, Heitler M, Rubin LG. Prognosis of herpes zoster in healthy children. Am J Dis Child. 1986;140(5): 477-8.
97. Sorensen HT, Olsen JH, Jepsen P, Johnsen SP, Schonheyder HC, Mellemkjaer L. The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study. Br J.Cancer 2004;91(7):1275-9.
98. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R, et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis. 1992;166(5):1153-6.
99. Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, et al. Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS. 1995;9(10):1153-8.
100. Chodick G, Ashkenazi S, Livni G, Lerman Y. Cost-effectiveness of varicella vaccination of healthcare workers. Vaccine. 2005;23(43):5064-72.
101. Schmutzhard J, Merete RH, Zweygberg WB, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol. 2004;29(2):120-6.
102. Stranska R, Schuurman R, de Vos M, van Loon AM. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. J Clin Virol 2004;30(1):39-44.
103. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics. 2000;105(1 Pt 1):136-41.
104. Seward JF. Update on varicella. Pediatr Infect Dis J. 2001; 20(6):619-21.
105. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001;344(13):955-60.
106. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23(2):132-7.
107. Vazquez M, LaRussa PS, Gershon AA, Niccolai LM, Muehlenbein CE, Steinberg SP, et al. Effectiveness over time of varicella vaccine. JAMA. 2004;291(7):851-5.
108. Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347(24):1909-15.
109. Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics. 2004;114(3):786-92.
110. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics. 1997;99(1):35-9.
111. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med. 1991;325(22): 1545-50.
112. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1): 26-34.
113. Schweizerische Kommission für Impffragen des Bundesamtes für Gesundheit. Varizellenimpfung. BAG Bulletin. 2004;45: 846-8.